The pandemic-era shift to remote work permanently changed assumptions about where executive support work must be performed. For pharmaceutical CEOs, who travel extensively and work across time zones by necessity, the question of whether their personal assistant needs to be physically present at all times has become more nuanced. Virtual personal assistant arrangements, in which the PA works primarily or entirely remotely, are increasingly viable for certain aspects of pharmaceutical CEO support. Understanding what works well in a virtual arrangement, what requires physical presence, and how to structure an effective hybrid model is essential for any pharmaceutical executive considering this approach.
What “Virtual PA” Means in Practice
The term “virtual personal assistant” covers a range of arrangements. At one end of the spectrum, a fractional virtual assistant service provides part-time remote administrative support from a pool of general assistants. At the other end, a dedicated virtual PA is a full-time, professionally qualified executive assistant who happens to work primarily from a remote location.
For pharmaceutical CEOs, the relevant question is rarely about fractional virtual assistant services, which typically lack the industry knowledge, confidentiality standards, and relationship depth required for pharmaceutical executive support. The more meaningful question is whether a dedicated, experienced pharmaceutical PA needs to be co-located with the CEO, or whether remote working arrangements can accommodate the demands of the role.
The answer depends heavily on the specific pharmaceutical context: the company’s stage, the CEO’s working style, and the nature of the PA’s core responsibilities.
What Works Well in a Virtual Arrangement
A significant portion of a pharmaceutical CEO’s PA work is inherently location-independent and functions effectively in a virtual arrangement.
Calendar and schedule management: Scheduling, meeting coordination, and calendar management are entirely digital activities that require no physical presence. The PA who manages a pharmaceutical CEO’s schedule from a remote office is just as effective as one who sits outside the CEO’s door, provided they are consistently available during working hours and have established clear communication protocols.
Travel management: Flight booking, hotel reservations, ground transportation coordination, visa applications, and all other travel logistics are digital activities. Many excellent corporate travel managers work entirely remotely and provide superior service to their clients across time zones.
Investor relations support: Coordinating investor meetings, preparing briefing materials, managing the earnings call schedule, and supporting the IR team’s CEO-facing activities are all manageable from a remote location.
Board communications: Preparing board packets, managing the board portal, tracking action items, and coordinating with the corporate secretary are document-intensive activities that can be managed remotely with appropriate security tools and access.
Written communications management: Managing the CEO’s email, drafting correspondence, and managing communication flows are inherently digital activities that work well remotely.
Conference management: Much of the preparation for conferences, including registration, hotel booking, and meeting scheduling, is done weeks in advance through digital channels.
What May Require Physical Presence
Some aspects of pharmaceutical CEO support are less well-suited to purely virtual arrangements.
In-person events and meetings: When the CEO hosts in-person meetings at company facilities, including board meetings, investor days, scientific advisory board meetings, and all-hands events, having the PA physically present to manage logistics in real time is valuable. Remote coordination of an in-person event is possible but creates more management friction.
Crisis situations: During a pharmaceutical crisis, when the CEO may be conducting intensive meetings and making rapid decisions, having the PA physically present enables the kind of real-time responsiveness that remote arrangements cannot fully replicate.
Highly confidential document handling: Some confidential materials, such as printed board materials or physical due diligence documents, may require physical handling that a remote PA cannot provide.
Relationship-building within the office: The PA who is physically present in the office develops working relationships with executive team members and other colleagues that enable more effective coordination over time. Remote PAs must work harder to build these relationships.
The Hybrid Model
The most effective arrangement for many pharmaceutical CEO PA roles is a hybrid model: the PA works remotely for routine administrative work but is physically present at the office or with the CEO for high-demand periods and important events.
This model provides the flexibility of remote work while ensuring physical presence when it most matters. A PA who works from a remote office four days per week but is at headquarters for board meetings, operating committee meetings, and investor events provides most of the benefits of an on-site PA while maintaining the lifestyle flexibility that attracts and retains talented professionals.
For pharmaceutical CEOs who travel extensively, the hybrid model often evolves naturally: the CEO is rarely in the office five days per week, so the PA who is present on the days the CEO is present and manages remote support on travel days is effectively a hybrid arrangement.
Virtual Assistant Services for Pharma CEOs
Several professional virtual assistant services specialize in executive support, some with specific pharmaceutical or life sciences experience. These services provide dedicated VAs at various engagement levels, from part-time fractional support to full-time dedicated arrangements.
For smaller pharmaceutical companies where a full-time PA is not yet warranted, a professional virtual assistant service with pharmaceutical experience can be a cost-effective bridge. The service handles scheduling, travel, correspondence, and other administrative tasks at a cost that may be significantly below a full-time employee’s total compensation.
The limitations of virtual assistant services are significant for pharmaceutical executives, however. Security and confidentiality standards vary across services. Industry-specific knowledge must be evaluated carefully. The relationship depth that makes a great PA genuinely effective may take longer to develop with a service provider than with a dedicated employee.
Security and Confidentiality in Virtual Arrangements
Pharmaceutical companies handle material non-public information, clinical trial data, acquisition discussions, and regulatory strategy that are among the most sensitive categories of corporate information. Virtual PA arrangements introduce information security considerations that must be addressed explicitly.
Key considerations include: secure communication channels for confidential documents and discussions; device security requirements for the PA’s working equipment; data storage practices that comply with company data governance policies; and clear protocols for handling information that must not leave specific security perimeters.
Before establishing a virtual PA arrangement, the CEO and HR or security team should address these security considerations explicitly and establish clear requirements that any virtual PA must meet.
Evaluating Whether Virtual Works for You
The pharmaceutical CEO considering a virtual PA arrangement should assess several factors. How much of my current PA work is location-independent? What are the most important times when physical presence is needed? Can those be accommodated through a hybrid arrangement? Is the available talent pool in the virtual market comparable to what I could hire on-site? What are the security and confidentiality requirements that limit the virtual option?
CEOs who travel more than 50% of the time, who have relatively small offices where the executive team is rarely all together, and who have well-established digital work practices are the best candidates for effective virtual PA arrangements.
For more on what excellent pharmaceutical PA performance looks like in practice, see pharma PA duties. The pharma CEO assistant guide provides essential context for evaluating PA arrangements at pharmaceutical and biotech companies.
Conclusion
Virtual personal assistant arrangements are a viable and increasingly common option for pharmaceutical CEOs who are willing to invest in establishing the right tools, protocols, and communication practices to make them work. The key is honest assessment of which aspects of the role genuinely require physical presence and designing an arrangement that provides that presence when it matters while leveraging the flexibility and talent access advantages of virtual work for the substantial portion of the role that is location-independent. For pharmaceutical executives who get this balance right, virtual or hybrid PA arrangements can provide excellent support at competitive cost, with access to talent that might not be available or willing to work in a traditional on-site arrangement.
Related Reading
For further context, explore Virtual Personal Assistant for Biotech Startup CEOs and Virtual Personal Assistant for Finance CEOs: Benefits and Best Practices.